Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2011

01-12-2011 | Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

HIV-Related Research in Correctional Populations: Now is the Time

Authors: Josiah D. Rich, David A. Wohl, Curt G. Beckwith, Anne C. Spaulding, Nathaniel E. Lepp, Jacques Baillargeon, Adrian Gardner, Ann Avery, Frederick L. Altice, Sandra Springer, On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group

Published in: Current HIV/AIDS Reports | Issue 4/2011

Login to get access

Abstract

The incarcerated population has increased to unprecedented levels following the 1970 US declaration of war on illicit drug use. A substantial proportion of people with or at risk for HIV infection, including those with substance use and mental health disorders, have become incarcerated. The overlapping epidemics of incarceration and HIV present a need for academic medical centers to collaborate with the criminal justice system to improve the health of incarcerated populations. With coordinated collaboration and new programmatic initiatives it is possible to reduce HIV-associated risk behaviors and the likelihood of acquisition and transmission of HIV. Centers for AIDS Research (CFAR), funded by the National Institutes of Health, have proactively responded to this need through Collaboration on HIV in Corrections (CHIC) to improve the diagnosis, treatment, linkage to care, and prevention of HIV. This collaboration serves as a model for aligning academic expertise with criminal justice to confront this challenge to individual and public health. This is especially relevant given recent evidence of the effectiveness of antiretroviral therapy in reducing HIV transmission (Cohen et al. N Engl J Med 365(6):493–505, 2011).
Literature
1.
Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
2.
Pew Center on the States, One in 31: The Long Reach of American Corrections 2009: Washington, DC.
3.
Maruschak LM et al. Pandemic influenza and jail facilities and populations. Am J Public Health. 2009;99 Suppl 2:S339–44.PubMedCrossRef
4.
Spaulding AC et al. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558.PubMedCrossRef
5.
El-Sadr WM, Mayer KH, Hodder SL. AIDS in America–forgotten but not gone. N Engl J Med. 2010;362(11):967–70.PubMedCrossRef
6.
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and callfor evidence-based treatment for released prisoners. Am J Drug Alcohol Abuse. 2011;37(1):12–21.
7.
Springer SA et al. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–60.PubMedCrossRef
8.
Stephenson BL et al. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Rep. 2005;120(1):84–8.PubMed
9.
Stephenson BL et al. Sexual behaviours of HIV-seropositive men and women following release from prison. Int J STD AIDS. 2006;17(2):103–8.PubMedCrossRef
10.
•• Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration in the United States. N Engl J Med. 2011;364(22):2081-3. A disproportionate amount of incarceration in the US has been caused by the failed war on drugs and a failure to provide treatment to those with mental illnesses and addictions. While the medical and public health communities should capitalize on the opportunity to provide treatment to the largely uninsured, low-income, and minority population cycling through the criminal justice system, they also have the responsibility of advocating for alternatives to incarceration that address the health needs of underserved communities. PubMedCrossRef
11.
Raimer BG, Stobo JD. Health care delivery in the Texas prison system: the role of academic medicine. JAMA. 2004;292(4):485–9.PubMedCrossRef
12.
Beckwith CG et al. Feasibility and acceptability of rapid HIV testing in jail. AIDS Patient Care STDS. 2007;21(1):41–7.PubMedCrossRef
13.
Kavasery R et al. A prospective controlled trial of routine opt-out HIV testing in a men's jail. PLoS One. 2009;4(11):e8056.PubMedCrossRef
14.
Springer SA et al. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clin Trials. 2007;8(4):205–12.PubMedCrossRef
15.
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010;87(4):592–602.PubMedCrossRef
16.
Lazzarini Z, Altice FL. A review of the legal and ethical issues for the conduct of HIV-related research in prisons. AIDS Public Policy J. 2000;15(3–4):105–35.PubMed
17.
Sabol WJ, Minton TD, Harrison PM. Prison and jail inmates at midyear, 2006. U.S. Department of Justice, 2007. Document NCJ 217675.
18.
••Altice FL, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376(9738):367-87. This study provides an overview of comorbidities among HIV-positive people who use drugs and reviews treatment complications for those multiple conditions, particularly pharmacokinetic drug interactions and adherence problems.PubMedCrossRef
19.
Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med. 2003;24(3):249–53.PubMedCrossRef
20.
Mumola CJ, Karberg JC. Drug use and dependence, state and federal prisons, 2004. U.S. Department of Justice, 2006. Document NCJ 213530.
21.
Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008(2):CD002207.
22.
Binswanger IA et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.PubMedCrossRef
23.
Palepu A et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361–8.PubMedCrossRef
24.
Kinlock TW et al. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277–85.PubMedCrossRef
25.
Karberg J, James D. Substance dependence, abuse, and treatment of jail inmates, 2002. 2005: Washington, D.C.
26.
Mumola C. Substance abuse and treatment, state and federal prisoners, 1997. Justice UDo, 1999:1-16.
27.
Hendershot CS et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.PubMedCrossRef
28.
Palepu A et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health. 2003;80(4):667–75.PubMedCrossRef
29.
James DJ, Glaze LE. Mental health problems of prison and jail inmates. 2006. Bureau of Justice Statistics.
30.
Cook JA et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health. 2004;94(7):1133–40.PubMedCrossRef
31.
Rivas-Vazquez RA et al. A relationship-based care model for jail diversion. Psychiatr Serv. 2009;60(6):766–71.PubMedCrossRef
32.
Blankenship KM, Koester S. Criminal law, policing policy, and HIV risk in female street sex workers and injection drug users. J Law Med Ethics. 2002;30(4):548–59.PubMedCrossRef
33.
Petitt W, Western B. Mass imprisonment and the life course: race and class inequality in U.S. incarceration. Am Soc Rev. 2004;69:151–69.CrossRef
34.
Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health. 2002;92(11):1789–94.PubMedCrossRef
35.
Jurgens R et al. Panel: rights of people in prison to HIV prevention, treatment and care. HIV AIDS Policy Law Rev. 2009;14(2):84–92.PubMed
36.
37.
Dolan K, Larney S. A review of HIV in prisons in Nepal. Kathmandu Univ Med J (KUMJ). 2009;7(28):351–4.
38.
Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. Am J Public Health. 2006;96(6):974–8.PubMedCrossRef
39.
Marks G et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446–53.PubMedCrossRef
40.
Small W et al. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study. AIDS Care. 2009;21(6):708–14.PubMedCrossRef
41.
Kinlock TW et al. A study of methadone maintenance for male prisoners: 3 month post-release outcomes. Crim Justice Behav. 2008;35(1):34–47.PubMedCrossRef
42.
••Baillargeon J, et al. Accessing antiretroviral therapy followiong release from prison. JAMA 2009;301(8):848-57. This study of 2115 HIV-positive inmates in Texas found significant interruptions in ART following release from prison, with only 5% of subjects filling a subsidized prescription within 10 days of release and 30% filling it within 60 days of release. This interruption in treatment creates heightened risks for adverse clinical outcomes, reservoirs of drug-resistant HIV, and greater infectiousness. PubMedCrossRef
43.
Maru DS, Basu S, Altice FL. HIV control efforts should directly address incarceration. Lancet Infect Dis. 2007;7(9):568–9.PubMedCrossRef
44.
Khan MR, et al. Dissolution of primary intimate relationships during incarceration and associations with post-release STI/HIV risk behavior in a Southeastern City. Sex Transm Dis, 2010.
45.
Maruschak L. HIV in prisons, 2006, B.o.J.S. US Department of Justice, Editor. 2007.
46.
Dixon PS et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med. 1993;95(6):629–35.PubMedCrossRef
47.
Baillargeon J et al. Psychiatric disorders and suicide in the nation's largest state prison system. J Am Acad Psychiatry Law. 2009;37(2):188–93.PubMed
48.
Wakeman SE, McKinney ME, Rich JD. Filling the gap: the importance of Medicaid continuity for former inmates. J Gen Intern Med. 2009;24(7):860–2.PubMedCrossRef
49.
Zahari MM et al. Psychiatric and substance abuse comorbidity among HIV seropositive and HIV seronegative prisoners in Malaysia. Am J Drug Alcohol Abuse. 2010;36(1):31–8.PubMedCrossRef
50.
Stuckler D et al. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci U S A. 2008;105(36):13280–5.PubMedCrossRef
51.
Podlekareva DN et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS. 2009;23(18):2485–95.PubMedCrossRef
Metadata
Title
HIV-Related Research in Correctional Populations: Now is the Time
Authors
Josiah D. Rich
David A. Wohl
Curt G. Beckwith
Anne C. Spaulding
Nathaniel E. Lepp
Jacques Baillargeon
Adrian Gardner
Ann Avery
Frederick L. Altice
Sandra Springer
On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-011-0095-3

Other articles of this Issue 4/2011

Current HIV/AIDS Reports 4/2011 Go to the issue

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Substance Use: Impact on Adherence and HIV Medical Treatment

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Mental Health: A Focus on Stress, Coping, and Mental Illness as it Relates to Treatment Retention, Adherence, and Other Health Outcomes

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Secondary HIV Prevention: Novel Intervention Approaches to Impact Populations Most at Risk

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Neurocognitive Impact of Antiretroviral Treatment: Thinking Long-Term

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Link to Slower Access to Care: What is the Stigma? An Indian Perspective
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits